FDA approves Roche’s Xofluza to prevent flu spreading in familiesThe FDA has approved a new use for Xofluza (baloxavir marboxil) from Roche’s Genentech unit, to prevent people Share XFDA approves Roche’s Xofluza to prevent flu spreading in familieshttps://pharmaphorum.com/news/fda-approves-roches-xofluza-to-prevent-flu-spreading-in-families/
Lead Pharma signs $308m immune drug deal with RocheLead Pharma has signed a potential 260 million euro ($308 million) deal with Roche to develop small molecule Share XLead Pharma signs $308m immune drug deal with Rochehttps://pharmaphorum.com/news/lead-pharma-signs-308m-deal-to-develop-small-molecule-drugs-with-roche/
Roche’s Herceptin/Perjeta combo product nears EU approvalThe EMA’s human medicines committee has recommended approval of a fixed-dose combination of Roche’s breast cancer drugs Herceptin Share XRoche’s Herceptin/Perjeta combo product nears EU approvalhttps://pharmaphorum.com/news/roches-herceptin-perjeta-combo-product-nears-eu-approval/
NICE okays Roche liver cancer immunotherapy, Sanofi’s rare disease drugPreviously-untreated patients with hepatocellular carcinoma (HCC), a common form of liver cancer, will have an immunotherapy-based treatment option Share XNICE okays Roche liver cancer immunotherapy, Sanofi’s rare disease drughttps://pharmaphorum.com/news/nice-okays-roche-liver-cancer-immunotherapy-sanofis-rare-disease-drug/
NICE backs chemo-free CLL combination from AbbVie and RochePreviously untreated patients with chronic lymphocytic leukaemia (CLL) in England will get a chemotherapy-free treatment option after NICE Share XNICE backs chemo-free CLL combination from AbbVie and Rochehttps://pharmaphorum.com/news/nice-backs-chemo-free-cll-combination-from-abbvie-and-roche/
Sanofi/Alnylam’s haemophilia drug hits another safety speed-bumpSanofi’s attempt to take on Roche with a ground-breaking approach to treating haemophilia has hit a setback after Share XSanofi/Alnylam’s haemophilia drug hits another safety speed-bumphttps://pharmaphorum.com/news/sanofi-alnylans-haemophilia-drug-hits-another-safety-speed-bump/
Europe approves Roche’s Tecentriq liver cancer combinationThe European Commission has approved Roche’s Tecentriq immunotherapy, in combination with its established cancer drug Avastin, for patients Share XEurope approves Roche’s Tecentriq liver cancer combinationhttps://pharmaphorum.com/news/europe-approves-roches-tecentriq-liver-cancer-combination/
Roche to co-develop remdesivir rival in partnership with AteaRoche may not be the first company that comes to mind for a COVID-19 treatment, but the Swiss Share XRoche to co-develop remdesivir rival in partnership with Ateahttps://pharmaphorum.com/news/roche-to-co-develop-remdesivir-rival-in-partnership-with-atea/
FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapiesCombination therapies involving Roche and AbbVie’s cancer drug Venclexta have been formally approved by the FDA in acute Share XFDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapieshttps://pharmaphorum.com/news/fda-grants-full-approval-for-roche-abbvies-venclexta-in-aml-combination-therapies/
